These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 30403910)

  • 1. Safety of two doses of an inactivated hepatitis a vaccine given 6 months apart in healthy toddlers, children, and adolescents aged 12 months to 15 years in China: a phase IV study.
    Shi N; Rasuli A; Thollot Y
    Hum Vaccin Immunother; 2019; 15(3):748-754. PubMed ID: 30403910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open, prospective, randomized study comparing the immunogenicity and safety of two inactivated hepatitis A pediatric vaccines in toddlers, children and adolescents in China.
    Li RC; Li Y; Yi N; Huang L; Wan Z; Zhang Y; Rasuli A
    Pediatr Infect Dis J; 2013 Feb; 32(2):e77-81. PubMed ID: 23334341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the immunogenicity and safety of 3 inactivated hepatitis A vaccines in Korean children aged 12 to 18 months: An open-label, randomized, prospective, multicenter study.
    Hong SS; Choi UY; Ma SH; Lee SY; Han SB; Kim KH; Kang JH; Kim JH
    Medicine (Baltimore); 2019 Feb; 98(6):e14364. PubMed ID: 30732169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity, safety, and interchangeability of two inactivated hepatitis A vaccines in Chilean children.
    Abarca K; Ibánez I; Perret C; Vial P; Zinsou JA
    Int J Infect Dis; 2008 May; 12(3):270-7. PubMed ID: 17988917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the safety and immunogenicity of live attenuated and inactivated hepatitis A vaccine in healthy Chinese children aged 18 months to 16 years: results from a randomized, parallel controlled, phase IV study.
    Ma F; Yang J; Kang G; Sun Q; Lu P; Zhao Y; Wang Z; Luo J; Wang Z
    Clin Microbiol Infect; 2016 Sep; 22(9):811.e9-811.e15. PubMed ID: 27345175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of an inactivated hepatitis A vaccine when coadministered with Diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines in children 15 months of age.
    Trofa AF; Klein NP; Paul IM; Michaels MG; Goessler M; Chandrasekaran V; Blatter M
    Pediatr Infect Dis J; 2011 Sep; 30(9):e164-9. PubMed ID: 21494175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seven-year follow-up of the immune response after one or 2 doses of inactivated hepatitis A vaccine given at 1 year of age in the Mendoza Province of Argentina.
    Espul C; Benedetti L; Linares M; Cuello H; Lo Castro I; Thollot Y; Rasuli A
    Hum Vaccin Immunother; 2017 Nov; 13(11):2707-2712. PubMed ID: 28933624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of an inactivated hepatitis A vaccine in Taiwanese adults and children.
    Lee CY; Huang LM; Lee PI; Chiu HH; Dumas R; Milcamps B; Lin W
    Southeast Asian J Trop Med Public Health; 2000 Mar; 31(1):29-36. PubMed ID: 11023061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of an inactivated hepatitis A vaccine administered concomitantly with diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines to children less than 2 years of age.
    Nolan T; Bernstein H; Blatter MM; Bromberg K; Guerra F; Kennedy W; Pichichero M; Senders SD; Trofa A; Collard A; Sullivan DC; Descamps D
    Pediatrics; 2006 Sep; 118(3):e602-9. PubMed ID: 16950952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single blind randomized phase 3 study to evaluate safety and immunogenicity of inactivated hepatitis A vaccine (HAPIBEV
    Thuluva S; Matur R; Tsa K; Gv SR
    Vaccine; 2021 Dec; 39(49):7166-7174. PubMed ID: 34763950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis A vaccination of Argentinean infants: comparison of two vaccination schedules.
    López EL; Contrini MM; Xifró MC; Cattaneo MA; Zambrano B; Dumas R; Rouyrre N; Weber F
    Vaccine; 2007 Jan; 25(1):102-8. PubMed ID: 16914234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical experience with the inactivated hepatitis A vaccine, Avaxim 80U Pediatric.
    Bravo C; Mege L; Vigne C; Thollot Y
    Expert Rev Vaccines; 2019 Mar; 18(3):209-223. PubMed ID: 30806110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of a pediatric formulation of inactivated hepatitis A vaccine in Argentinean children.
    López EL; Del Carmen Xifró M; Torrado LE; De Rosa MF; Gómez R; Dumas R; Wood SC; Contrini MM
    Pediatr Infect Dis J; 2001 Jan; 20(1):48-52. PubMed ID: 11176566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of a pediatric dose of a virosomal hepatitis A vaccine in healthy children in India.
    Jain H; Kumavat V; Singh T; Versteilen A; Sarnecki M
    Hum Vaccin Immunother; 2014; 10(7):2089-97. PubMed ID: 25424821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of two doses of a paediatric hepatitis A vaccine in thai children: comparison of three vaccination schedules.
    Lolekha S; Pratuangtham S; Punpanich W; Bowonkiratikachorn P; Chimabutra K; Weber F
    J Trop Pediatr; 2003 Dec; 49(6):333-9. PubMed ID: 14725410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination against hepatitis A in children aged 12 to 24 months [corrected].
    Abarca K; Ibañez I; Flores J; Vial PA; Safary A; Potín M
    Arch Med Res; 2001; 32(5):468-72. PubMed ID: 11578765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of a novel 10-valent pneumococcal conjugate vaccine candidate in adults, toddlers, and infants in The Gambia-Results of a phase 1/2 randomized, double-blinded, controlled trial.
    Clarke E; Bashorun AO; Okoye M; Umesi A; Badjie Hydara M; Adigweme I; Dhere R; Sethna V; Kampmann B; Goldblatt D; Tate A; Weiner DH; Flores J; Alderson MR; Lamola S
    Vaccine; 2020 Jan; 38(2):399-410. PubMed ID: 31843266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term Serologic Follow-up of Children Vaccinated with a Pediatric Formulation of Virosomal Hepatitis A Vaccine Administered With Routine Childhood Vaccines at 12-15 Months of Age.
    Dagan R; Ashkenazi S; Livni G; Go O; Bagchi P; Sarnecki M
    Pediatr Infect Dis J; 2016 Jul; 35(7):e220-8. PubMed ID: 27093164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of a combined DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course and a booster dose in healthy children in Russia: a phase III, non-randomized, open-label study.
    Romanenko V; Osipova I; Galustyan A; Scherbakov M; Baudson N; Farhi D; Anaya L; Kuriyakose SO; Meyer N; Janssens W
    Hum Vaccin Immunother; 2020 Sep; 16(9):2265-2273. PubMed ID: 32048889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial.
    Han B; Song Y; Li C; Yang W; Ma Q; Jiang Z; Li M; Lian X; Jiao W; Wang L; Shu Q; Wu Z; Zhao Y; Li Q; Gao Q
    Lancet Infect Dis; 2021 Dec; 21(12):1645-1653. PubMed ID: 34197764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.